WHO refreshes the global baseline for which insecticides still work against mosquitoes

On 11 June 2026, the World Health Organization published updated guidance on discriminating concentrations and methods for monitoring insecticide resistance in mosquito vectors. The release is the international baseline document that national malaria and Aedes control programmes use to decide which chemistries still work and where resistance has spread. It is not consumer-facing, but it shapes every decision a national programme will make about indoor residual spraying, insecticide-treated nets, and space-spray responses for the next operational cycle.

What a "discriminating concentration" is, in one paragraph

A discriminating concentration is the dose of an insecticide that, in a standardised bioassay, kills nearly all susceptible mosquitoes and lets resistant ones survive. When field-caught mosquitoes survive the discriminating dose at a rate above a defined threshold, the population at that site is declared resistant to that chemistry. The discriminating concentration is therefore the operational cut-off: it is what turns a laboratory number into a national purchasing decision.

Why the update matters in 2026

Three pressures made the refresh necessary:

• Pyrethroid resistance has gone global. Pyrethroids are the dominant chemistry on insecticidal-treated nets and in many indoor residual spraying programmes. WHO's own Malaria Threats Map records pyrethroid resistance in 48 of 53 reporting African countries and in most Aedes populations sampled in South and Southeast Asia. The discriminating concentrations set when pyrethroid resistance was first detected in West African Anopheles gambiae in the early 2010s no longer reflect the dose-response curve of contemporary field populations.
• New active ingredients need new cut-offs. The last decade has added three chemistry classes to the public-health insecticide toolkit: neonicotinoids (clothianidin in next-generation IRS products such as SumiShield), pyrroles (chlorfenapyr), and insect growth regulators (pyriproxyfen for auto-dissemination). Each class has required its own discriminating-concentration validation. WHO has used the 2026 update to consolidate the cut-offs for these chemistries in a single reference document.
• Aedes resistance has outrun Aedes surveillance. For Aedes aegypti and Aedes albopictus, national pyrethroid resistance data is patchier than for Anopheles, and the recent spread of novel voltage-gated sodium channel mutations in Malaysian Ae. albopictus and metabolic-resistance alleles in Saudi Arabian Ae. aegypti (Al-Madinah Al-Munawarah) means the discriminating doses calibrated on long-established populations need to be re-validated. WHO has not yet solved the underlying surveillance gap, but the 2026 update tightens the bioassay protocol and the reporting format.

What the 2026 update does

• Consolidates the discriminating concentrations for pyrethroids (alpha-cypermethrin, deltamethrin, lambda-cyhalothrin, permethrin), organochlorines (DDT), organophosphates (malathion, pirimiphos-methyl), carbamates (bendiocarb, propoxur), neonicotinoids (clothianidin), pyrroles (chlorfenapyr), and insect growth regulators (pyriproxyfen) into a single reference.
• Updates the bioassay protocol (WHO tube test and WHO cone test) for the contemporary mosquito populations, including Aedes.
• Standardises the resistance-frequency thresholds used to declare a population "suspected resistant" or "confirmed resistant", and clarifies the operational consequences (switch to a new chemistry class, add a synergist, intensify larval-source management).
• Aligns the monitoring format with the data fields in the WHO Malaria Threats Map, so that national programmes reporting through the Threats Map see their data interpreted against the current cut-offs rather than the 2010s ones.

What the update does not do

It does not solve the underlying problem. Resistance is still spreading faster than the surveillance system can detect it. The document tightens the analytical method, not the field-deployment cadence. National programmes that are already stretched will continue to be stretched. Pyrethroid resistance will continue to drive the substitution toward neonicotinoid-treated nets (Interceptor G2 and similar products), combination-treated nets (pyrethroid plus pyrrole), and PBO-synergist nets where the resistance alleles are metabolic. None of this is news to a national programme manager; what is news is that the global reference document is now updated to match the 2026 chemistry mix.

What to do

• For national malaria and Aedes control programme managers: download the 2026 WHO update, refresh your bioassay protocol, and update the resistance-thresholds table in your programme manual. Cross-check the thresholds against the WHO Malaria Threats Map resistance-frequency data for your country.
• For academic and operational researchers: the 2026 update creates a clean before/after to evaluate field populations against. The novel V1016G / F1534C kdr alleles in Southeast Asian Aedes and the new VGSC mutations in Malaysian populations are the obvious calibration targets.
• For consumer-protection messaging: the update does not change what a household should do. The pyrethroid resistance story is the structural reason that home-front personal protection (skin-applied repellent, barrier clothing, treated bed nets, screened windows) is now a permanent part of the answer, not an emergency supplement to it.

Published 2026-06-12 · Mosticare Editorial